Infantile Spasms
Conditions
Brief summary
Infantile spasms constitute a unique age specific epilepsy syndrome of infancy, characterized by epileptic spasms often accompanied by neurodevelopmental regression and an EEG finding of hypsarrhythmia. When all 3 components are present, the eponym West syndrome is commonly used. West syndrome is a catastrophic epileptic encephalopathy. It does not respond well to standard anti-epileptic drugs. Hormonal therapy is the mainstay in the treatment of infantile spasms. This includes adreno-cortico trophic hormone (ACTH) and oral steroids. Variable dose of prednisolone used in the treatment. Oral prednisolone used in usual dose (2mg/kg) has been shown to be less effective as compared to ACTH. High dose prednisolone (4mg/kg) has been used in the treatment of infantile spasms, which has been shown to be as effective as ACTH. Pyridoxine has been used as first line treatment in Japan, however there is paucity of data on the efficacy of combination of pyridoxine with hormonal therapy. There are no studies comparing add on pyridoxine with high prednisolone versus high dose prednisolone alone in the treatment of infantile spasms. Therefore the study has been planned to see whether the addition of pyridoxine with high dose prednisolone in the treatment of infantile spasms improves the efficacy in terms of spasm cessation.
Interventions
DRUGPyridoxine plus prednisolone
DRUGPrednisolone
Sponsors
Lady Hardinge Medical College
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Months to 36 Months
Healthy volunteers
No
Inclusion criteria
1. Age in 3months-3years. 2. Presence of epileptic spasms (1 or more clusters per day) with EEG evidence of hypsarrythmia or its variants. \-
Exclusion criteria
1. Children with active systemic illness 2. Children with evidence of active tuberculosis 3. Severe Acute Malnutrition (standard deviation scores below median weight for height) 4. Children with recurrent illness/chronic systemic illness 5. Prior treatment of pyridoxine, steroid, or ACTH. \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of children who achieved complete cessation spasm for at least 48 hours as per parental reports at the end of 2 weeks in both the groups. | 2 weeks | Proportion of children who achieved complete cessation spasm for at least 48 hours as per parental reports at the end of 2 weeks in both the groups. |
Secondary
| Measure | Time frame |
|---|---|
| • Proportion of children who achieved more than 50 % reduction of clinical spasms as per parental reports at the end of 2 weeks | 2 weeks |
Countries
India
Outcome results
None listed